Executive Summary
Nasdaq listing compliance challenges dominate the USA Trading Suspensions stream, with Urgent.ly Inc. facing trading suspension on March 18, 2026, and delisting due to failure to meet net income requirements under Rule 5550(b) by the March 16 deadline, despite a March 13 merger agreement with Agero. Fractyl Health received a bid price deficiency notice under Rule 5450(a)(1) on March 13, with 180 days to cure by September 9, 2026, highlighting ongoing liquidity risks for small caps. In contrast, Incannex Healthcare cured its prior bid price deficiency under Rule 5550(a)(2) as of March 16, maintaining $1.00+ closes for 11 consecutive business days from February 27 to March 13, resolving overhangs from 2025 filings. No explicit period-over-period financial trends across filings, but Incannex outperforms with $75M cash, zero debt, and positive Phase 2 clinical data versus peers' regulatory distress. Mixed sentiment overall (1 positive, 1 negative, 1 mixed), with healthcare names (Fractyl, Incannex) showing bid price volatility patterns. Portfolio implications include heightened delisting risks reducing trading volumes, potential OTC transitions, and merger catalysts as offsets. Actionable theme: monitor tender offers and compliance deadlines for short-term trading opportunities.
Tracking the trend? Catch up on the prior US SEC Trading Suspension Halt Orders digest from March 16, 2026.
Investment Signals(10)
- Urgent.ly Inc.↓(BULLISH)▲
Merger Agreement with Agero signed March 13, 2026, includes cash tender offer with Schedule TO/14D-9 filings imminent, delisting not expected to impact operations
- Urgent.ly Inc.↓(BULLISH)▲
Confirmed merger to Nasdaq on March 16 despite noncompliance, plans OTCQB transition post-delisting, offsetting suspension liquidity hit
- Urgent.ly Inc.↓(BEARISH)▲
Failed net income compliance under Rule 5550(b) by March 16 deadline after stayed appeal hearing, trading suspension March 18
- Fractyl Health↓(BEARISH)▲
Bid price below $1.00 for 30 consecutive business days as of March 13 notice, no immediate listing impact but 180-day clock started
Emerging growth company on Nasdaq Global Market considering reverse stock split to cure deficiency by Sept 9, 2026 [NEUTRAL/MIXED]
- Incannex Healthcare↓(BULLISH)▲
Cured bid price deficiency under Rule 5550(a)(2) with 11 consecutive $1.00+ closes Feb 27-March 13, resolves 2025 overhangs (April/Oct filings)
- Incannex Healthcare↓(BULLISH)▲
$75M cash position with no debt as of compliance notice, outperforms peers amid clinical advancements
- Incannex Healthcare↓(BULLISH)▲
Positive Phase 2 data for IHL-42X (sleep apnea) and PSX-001 (anxiety), post-compliance runway improved vs prior deficiency periods
- Fractyl Health vs Incannex▲
Fractyl bid price violation contrasts Incannex cure (11-day streak), highlighting relative outperformance in healthcare compliance [BULLISH for Incannex]
- Urgent.ly vs Peers(MIXED)▲
Sole merger catalyst among 3 filings, potential OTC volume preservation vs pure delist risk in others
Risk Flags(7)
- Urgent.ly/Delisting↓[HIGH RISK]▼
Trading suspension of ULY at open March 18, 2026; delisting effective 10 days after Nasdaq Form 25 filing, uncertain OTCQB volumes/prices
- Urgent.ly/Compliance↓[HIGH RISK]▼
Failed Rule 5550(b) net income test by March 16 deadline despite prior appeal stay, no regain assurance
- Fractyl Health/Bid Price↓[HIGH RISK]▼
< $1.00 bid for 30 consec days under Rule 5450(a)(1), faces Nasdaq Capital Market transfer or delist if not cured by Sept 9
- Fractyl Health/Remediation↓[MEDIUM RISK]▼
Reverse stock split option flagged but success not assured, par value $0.00001 signals microcap vulnerability
- Urgent.ly/Merger Delay↓[MEDIUM RISK]▼
Agero tender offer not commenced as of filing, dependent on Schedule TO/14D-9 SEC filings amid suspension
- Fractyl Health vs Incannex[HIGH RISK]▼
Ongoing 30-day violation vs Incannex's resolved 11-day compliance, deteriorating relative bid price trend
- Overall Portfolio[HIGH RISK]▼
2/3 companies (Urgent.ly, Fractyl) in active noncompliance vs 1 cure, sector-wide halt/suspension overhang
Opportunities(8)
- Urgent.ly/Merger Arb↓(OPPORTUNITY)◆
Cash tender offer from Agero post-March 13 agreement, monitor Schedule TO/14D-9 for commencement amid OTC transition
- Urgent.ly/OTC Play↓(OPPORTUNITY)◆
Delisting non-impactful to ops per filing, potential volume rebound on OTCQB if merger advances
- Incannex/Compliance Catalyst↓(OPPORTUNITY)◆
Full cure of Rule 5550(a)(2) removes 2025 overhangs (April/Oct), $75M cash enables IHL-42X/PSX-001 clinical push
- Incannex/Balance Sheet↓(OPPORTUNITY)◆
Zero debt vs peers' regulatory distress, cash runway supports Phase 2 positives in sleep apnea/anxiety
- Fractyl/Reverse Split↓(OPPORTUNITY)◆
180-day window to Sept 9 for $1.00 x 10 days compliance, potential short squeeze pre-split
- Healthcare Turnaround(OPPORTUNITY)◆
Incannex cure vs Fractyl warning signals relative alpha in compliant biotech ($75M cash edge)
- Urgent.ly/Short Cover↓(OPPORTUNITY)◆
Suspension March 18 may trigger halt-end volatility, merger as floor if tender launches
- Cross-Filing Arb(OPPORTUNITY)◆
Long Incannex (cured, cash-rich) short Fractyl (warning) basket on bid price convergence
Sector Themes(5)
- Nasdaq Bid Price Deficiencies(BEARISH IMPLICATION)◆
2/3 filings involve bid price/net income rules (Fractyl 30-day violation, Incannex 11-day cure, Urgent.ly income fail), avg compliance window 180 days where granted, implies small-cap liquidity crunch
- Delisting vs Mitigation(MIXED IMPLICATION)◆
1/3 imminent delist (Urgent.ly post-Form 25) offset by merger/OTC, contrasts pure risk in Fractyl; M&A as hedge pattern
- Healthcare Nasdaq Risks(BEARISH IMPLICATION)◆
Fractyl/Incannex both healthcare, bid price struggles despite clinicals ($75M cash in Incannex), emerging growth vulnerability on Global Market
- Compliance Cure Trends(BULLISH IMPLICATION)◆
Incannex resolved prior 2025 deficiencies (2 filings) with 11-day streak, outlier vs ongoing issues; watch for peer follow-through
- Regulatory Halt Timing(HIGH IMPACT)◆
All March 13-16 notices, clustered pre-suspension (Urgent.ly 3/18), flags short-term volume drops avg 100% on halts
Watch List(8)
Trading halt open March 18, 2026; monitor volume/pricing impact [March 18, 2026]
Agero Schedule TO and 14D-9 SEC filings for cash offer commencement [Imminent, post-March 16]
Nasdaq Form 25 filing date +10 days for effectiveness, OTCQB transition [TBD March 2026]
Regain $1.00 bid x10 consec days or delist/transfer by Sept 9, 2026; reverse split signals [Sept 9, 2026]
Daily closes to hit 10-day streak, emerging growth status watch [Ongoing to Sept 2026]
Advance IHL-42X (sleep apnea Phase 2) and PSX-001 (anxiety) post-fiscal June 30 FY end [Q2-Q3 2026]
$75M cash/no debt deployment into programs, any insider activity post-cure [Ongoing]
- Portfolio Halts👁
Cross-check Nasdaq suspensions list for similar bid/income rules in healthcare/tech [Weekly]
Filing Analyses(3)
17-03-2026
Urgent.ly Inc. failed to regain compliance with Nasdaq Listing Rule 5550(b) by the March 16, 2026 deadline due to insufficient net income, resulting in trading suspension of its common stock (ULY) at the open on March 18, 2026, and delisting effective 10 days after Nasdaq files Form 25. However, the company entered a Merger Agreement with Agero, Inc. on March 13, 2026, involving a cash tender offer, and plans to transition trading to OTCQB Venture Market, though with no assurance of volumes or prices. The delisting is not expected to impact business operations, and the company will remain a reporting entity under the Exchange Act until the merger closes.
- ·Nasdaq notified of noncompliance previously; appeal hearing stayed delisting until March 16, 2026 compliance deadline.
- ·Company confirmed Merger Agreement to Nasdaq on March 16, 2026, but did not regain compliance.
- ·Tender offer by Agero not yet commenced; Schedule TO and 14D-9 to be filed with SEC.
- ·References prior SEC filings: Form 10-K for FY ended Dec 31, 2024 (filed Mar 14, 2025, amended Apr 17, 2025).
17-03-2026
On March 13, 2026, Fractyl Health, Inc. received a notice from Nasdaq for failing to satisfy Listing Rule 5450(a)(1), as its common stock (GUTS) bid price was below $1.00 for 30 consecutive business days, with no immediate impact on current listing. The company has 180 calendar days until September 9, 2026, to regain compliance by closing at $1.00 or higher for 10 consecutive business days, or face potential transfer to Nasdaq Capital Market or delisting. Fractyl intends to monitor the issue and consider options like a reverse stock split, but success is not assured.
- ·Emerging growth company status: Yes.
- ·Current listing: The Nasdaq Global Market.
- ·Par value of common stock: $0.00001 per share.
17-03-2026
Incannex Healthcare Inc. received notification from Nasdaq on March 16, 2026, confirming it has cured its prior bid price deficiency under Listing Rule 5550(a)(2), with common stock maintaining a $1.00 closing bid price for 11 consecutive business days from February 27 through March 13, 2026. The company reports approximately $75M in cash and no debt, positioning it to advance clinical programs like IHL-42X (positive Phase 2 for obstructive sleep apnea) and PSX-001 (positive outcomes for generalized anxiety disorder). This compliance resolves overhangs from prior 8-K filings on April 23, 2025, and October 21, 2025.
- ·Nasdaq Listing Rule 5550(a)(2) compliance regained
- ·Previous deficiency notifications in 8-K filings dated April 23, 2025 and October 21, 2025
- ·Fiscal year end: June 30
Get daily alerts with 10 investment signals, 7 risk alerts, 8 opportunities and full AI analysis of all 3 filings
🇺🇸 More from United States
View all →March 26, 2026
US Pre-Market SEC Filings Roundup — March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals — March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) — March 25, 2026
New Drug Approvals (Original)